Compare Endeavour Silver Corp (EXK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Endeavour Silver Corp trades at $10.58 (market cap $3.14B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | XBI | |
|---|---|---|
Market Cap | $3.14B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $14.12 | $164.28 |
52-Week Low | $5.31 | $86.92 |
Enterprise Value | $3.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $10.61, up 3.61% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.50. Recent Q2 2026 earnings matched estimates at $0.15 per share, while Q1 2026 beat expectations. The company reported strong production growth and secured a $25 million credit facility in August 2026, supporting operational expansion.
Outlook is positive due to rising revenue, improved profitability projected for 2026, and favorable metal prices. Risks include high P/E ratio of 52.95, volatile earnings history, and dependence on commodity markets. Institutional sentiment is bullish with 78.57% buy ratings.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
